Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Targeting metabolism in heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by